Evofem Biosciences, INC. (EVFM) SEC Filings — 2024

Filings

• Evofem Biosciences Changes Principal Executive Offices — 8-K · Dec 23, 2024
• Evofem Biosciences Enters Material Definitive Agreement — 8-K · Nov 25, 2024
• Evofem Biosciences Files Q3 2024 10-Q — 10-Q · Nov 14, 2024
• Evofem Biosciences Enters Material Definitive Agreement — 8-K · Nov 6, 2024
• Evofem Terminates Phexxi License Deal with 03 Life Sciences — 8-K · Oct 31, 2024
• Evofem Biosciences Files 8-K: Material Agreement & Equity Sales — 8-K · Oct 28, 2024
• Evofem Biosciences Files 8-K with Material Agreements & Equity Sales — 8-K · Oct 3, 2024
• Evofem Biosciences Enters Material Agreement, Files 8-K — 8-K · Sep 25, 2024
• Evofem Biosciences Enters Material Definitive Agreement — 8-K · Sep 6, 2024
• Evofem Biosciences to be Delisted from Nasdaq — 8-K · Aug 30, 2024
• Evofem Biosciences Enters Material Definitive Agreement — 8-K · Aug 20, 2024
• Evofem Biosciences Files Q2 2024 10-Q — 10-Q · Aug 14, 2024
• Evofem Biosciences Secures $10M Loan — 8-K · Jul 23, 2024
• Evofem Biosciences Files 8-K — 8-K · Jul 18, 2024
• Evofem Biosciences Holds Annual Meeting, Approves Key Proposals — 8-K · Jun 26, 2024
• Evofem Biosciences, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 15, 2024
• Evofem Biosciences Terminates Adare Pharma Deal, Enters New Agreement — 8-K · May 2, 2024
• Evofem Biosciences Files Current Report — 8-K · Mar 28, 2024
• Evofem Biosciences, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 27, 2024
• Evofem Biosciences Enters Material Definitive Agreement — 8-K · Mar 6, 2024
• Evofem Biosciences, INC. SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Evofem Biosciences Updates Principal Executive Office Address — 8-K · Feb 1, 2024
• Evofem Biosciences Reports Undisclosed Material Agreement — 8-K · Jan 31, 2024
• Evofem Biosciences Amends 8-K/A for Address Correction — 8-K/A · Jan 25, 2024
• Evofem Biosciences Reports Material Definitive Agreement; Details Undisclosed — 8-K · Jan 11, 2024